Sign inJoin waitlistJoin the waitlist

SM

Samuel Mehr

Instructor/Lecturer · Yale-New Haven Hospital

Credentials: · · · · ·

History

Yale-New Haven Hospital
Present
Yale-New Haven Hospital
Present

Nuclear Medicine
1976–1979
Harvard University, Human Development
Doctor of Medicine
1972–1976

Research

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
Pancreas · 2022 · 6 citations
Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer
Review · Oncology and Therapy · 2025 · First of 2 authors · Corresponding · 1 citations
Medicolegal applications of PET scans
Neurorehabilitation · 2001 · First of 2 authors · Corresponding · 1 citations

Andrew Hendifar
1 paper
Derek McHaffie
1 paper
IF
Ingrid Franze
1 paper · 1 as a resident
IM
Iris Moore
1 paper
RH
Ralph Hauke
1 paper
RF
Robert Faulk
1 paper · 1 as a resident

Clinical trials

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2032
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Perspective Therapeutics
2025–2032
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Site PI · Recruiting · Phase 1
Novartis Pharmaceuticals
2024–2028